Tracker by jurisdiction
Law and Policy
Ibogaine policy is moving quickly across states, countries, agencies, research programs, and private-sector activity. Each policy row needs to show what the source permits, what it does not permit, and what remains federally constrained.
Key Points
- State interest or funding does not override federal legal status in the United States.
- Trial authorization, IND activity, and policy study activity are not described as treatment approval.
- Country-by-country clinic availability and legal status are sourced and dated.
- Policy pages link to original bills, agency documents, and trial records whenever possible.
United States Baseline
Ibogaine remains federally controlled in the United States. State-funded research, legislative interest, executive orders, and FDA research actions do not create general treatment access.
FDA's April 2026 Noribogaine language allowed an early phase study to proceed after an IND submission and explicitly said the drug was not approved or found safe or effective.
State Activity To Track
- Texas: state-funded IMPACT research program and SB 2308-related drug-development language.
- Oklahoma: 2026 breakthrough-therapy legislation related to Ibogaine clinical trials and drug development.
- Tennessee and other states: bill language, fiscal notes, committee actions, and final status need primary-source confirmation.
Policy Reading Rules
- Use bill text and agency records before headlines.
- Separate research authorization, funding, trial recruitment, drug approval, prescribing, and clinic access.
- Show what a policy permits and what it does not permit.
- Date every row because law and agency language can change quickly.
Sources
Continue reading
Reader Boundary
Educational reference material only; not medical advice, legal advice, dosing instruction, provider referral, or emergency guidance. Emergency, treatment, and legal decisions belong with qualified professionals and local emergency systems.